AntibioticDB

Highest development stage: Preclinical

Development active

Gram-positive activity

Mechanism of Action/Target pathogen: Indolmycin is bacteriostatic and demonstrates good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus) and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid.

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11021

Source: https://aac.asm.org/content/18/6/858.short

Citation (1): https://academic.oup.com/jac/article/54/2/549/767563

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/135417159

Indolmycin

Aminoacyl-tRNA synthetase inhibitor (tryptophanyl-tRNA synthetase [TrpS] inhibitor)

Antimicrobial Research Centre and School of Biochemistry and Microbiology, University of Leeds, Leeds LS2 9JT, UK

1980